Pharsight

Astepro Allergy patents expiration

ASTEPRO ALLERGY IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 5 months from now)

US9919050 BAYER HLTHCARE Compositions comprising azelastine
Nov, 2025

(1 year, 5 months from now)

US8071073 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Jun, 2028

(3 years from now)

Astepro Allergy is owned by Bayer Hlthcare.

Astepro Allergy contains Azelastine Hydrochloride.

Astepro Allergy has a total of 3 drug patents out of which 0 drug patents have expired.

Astepro Allergy was authorised for market use on 17 June, 2021.

Astepro Allergy is available in spray, metered;nasal dosage forms.

Astepro Allergy can be used as otc use: allergy symptom reliever; temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose.

The generics of Astepro Allergy are possible to be released after 04 June, 2028.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

ASTEPRO ALLERGY family patents

Family Patents